Argyle Executive Forum’s Pharmaceuticals and Biotechnology Leadership Breakfast convenes approximately 30 – 40 senior officers from both large and midsized pharmaceutical and biotech companies as well as founders/senior managing partners of investment firms that focus on the sector. The Breakfast provides ample opportunities for informal conversations and networking, as well as formal panel presentations.

 Topics to be discussed may include but are not limited to:

• Investment trends in the pharmaceutical and biotech industries
• R&D and pipeline issues
• The environment for new drug development
• M&A activity in the sector

Event location is disclosed upon completion of the registration process. This event is by invitation only, and an invitation code is required. If you did not receive an invitation but would like to inquire about attendance, please click here.

Perspectives By:

Cathy Arnst
Healthcare Reporter
Bloomberg BusinessWeek

Roger G. Berlin, MD
Former President, Global R&D
Wyeth Consumer Healthcare

Mitchell Blutt
Chief Executive Officer
Consonance Capital

Chris Garabedian
Vice President, Corporate Strategy
Celgene Corporation

Herb Ormsbee, PhD
Former Executive Director, Licensing & Development
Pfizer

Kathryn E. Smith
Former Executive Director of Strategic Alliances
Pfizer

Dr. Robert J. Spiegel, M.D.
Former Chief Medical Officer and Senior Vice President, Schering-Plough Corporation
and
Founder, Spiegel Consulting LLC

A Joint Event With:

*Argyle Executive Forum's receptions are by invitation only. Argyle Executive Forum reserves the right to review and approve all attendees.